MG
ARKG icon

Michael Gelband’s ARK Genomic Revolution ETF ARKG Stock Holding History

Michael Gelband’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-46,624
Closed -$1.47M – 1857
2022
Q2 		$1.47M Buy
+46,624
New +$1.63M 0.02% 917
2020
Q3 		– Sell
-4,200
Closed -$219K – 1728
2020
Q2 		$219K Buy
+4,200
New +$180K 0.01% 1472

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Michael Gelband's ARKG Position: Q3 2022 in Review

Michael Gelband sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 46,624 shares — an estimated $1.47M sold.

Michael Gelband first reported a position in ARKG in Q2 2020 and held it in 2 quarters. The position peaked at $1.47M in Q2 2022. 312 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.

  • Michael Gelband reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
  • Michael Gelband sold 46,624 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $1.47M.
  • Michael Gelband first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 2 quarters.
  • Michael Gelband's ARK Genomic Revolution ETF position peaked at $1.47M in Q2 2022.
  • 312 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.